KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

IMpower010: 5-Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB-IIIA Non-Small Cell Lung Cancer.

Cancer Sci · 2026-Mar · PMID 41416818

Panel B提取完成待 EXE 对齐验证

OS

FIGURE 2 OS in Japanese patients with stage II–IIIA NSCLC by PD‐L1 status, a stage II–IIIA all‐randomized or stage IB–IIIA ITT populations. Kaplan–Meier estimates of OS in the (A) PD‐L1 TC ≥ 1%, (B) PD‐L1 TC 1%–49%, (C) PD‐L1 TC ≥ 50%, (D) stage II–IIIA all‐randomized, and (E) ITT populations are shown. a Evaluated by SP263 assay. BSC, best supportive care; CI, confidence interval; HR, hazard ratio; ITT, intention to treat; NE, not estimable; NSCLC, non‐small cell lung cancer; OS, overall survival; PD‐L1, programmed death 1 ligand; TC, tumor cell.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分1.00
质量通过是
预期曲线2
实际曲线2
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0complete待验证22026-07-18T19:24:33+00:00